The Efficacy Of Budesonide Inhalant On Broncahial Asthma In Children

Purpose:Broncahial asthma is the most common chronic childhood respiratory diseases, is a recurrent paroxysmal wheezing, difficulty breathing, chest tightness or coughing as the main clinical manifestations of. The past ten years, the incidence of asthma in our children a clear upward trend, a serious threat to children's health and quality of life. Asthma, chronic nature of airway inflammation and increased airway responsiveness and airway remodeling, it will be anti-inflammatory treatment for treating the first place, glucocorticoid with strong non-specific anti-inflammatory effect, while the direct effect of inhalation therapy in the respiratory tract, avoid serious side effects caused by systemic medication, so ICS as first-line treatment of children with asthma medication. Now more than advocate the use of nebulized inhalation solution or application of pump Spacer with mask pressure quantitative aerosol inhalation device, the clinical application of a broader, security is mainly the higher budesonide suspension, while the static point of dexamethasone is a traditional asthma treatment. This study aimed to explore the budesonide suspension for inhalation treatment of children with asthma and with the infusion of.Methods:①take 56 five-year-old to 12 year-old children, was diagnosed in our hospital for bronchial asthma, there is a 10-year history of asthma, the incidence within three days of admission. Assessment by a doctor has decided to use inhaled steroid and hormone infusion therapy.Exclusion criteria: For those who are allergic Budesonide; hospital 1 week before this study had used leukotriene receptor modulators,β2-receptor agonists, theophylline, histamine antagonists and hormone therapy, etc.; risk patients with asthma , respiratory failure, respiratory distress and a very critical degree of respiratory diseases. No chronic heart and lung, liver and kidney and other organ dysfunction and other chronic diseases, non-congenital heart and lung disease.②, for all patients in accordance with the ratio of 4:3 were randomly divided into experimental group and 32 control group of 24 persons, children in the regular course of the study given to spasm, anti-infection, oxygen, asthma and other symptomatic treatment. The test group of 100 Swiss children use German manufactured pump nebulized budesonide inhalation mixed liquid, 0.5mg~1mg / times, 2 times / day inhalation, the control group dexamethasone 5mg~10mg / times, 1 time / day Intravenous.③drug treatment before and after admission, after 1 week, 1 week, 2 weeks after the visits, a total of three times and signed informed consent, living wills material use, whether accompanied by other drugs, and self-evaluation condition. Observed and recorded as follows: cough, no, recorded as 0 points; minor, recorded as 1 point; obviously, activities were not affected, denoted by 2 points; seriously affect the activity, recorded as 3 minutes. Wheezing, mild, recorded as 0 points; moderate, often only a breath, recorded as 1 point; loud, denoted by 2 points; is usually loud, recorded as 3 points. Difficulty breathing, no, recorded as 0 points; mild, lips cyanosis was not obvious, recorded as 1 point; moderate and more pronounced lips cyanosis, denoted by 2 points; severe, lips cyanosis obvious, recorded as 3 minutes. Wheezing lungs, no, recorded as 0 points; scattered, breathing the end, denoted by 1 pm; loud, filled the air, denoted by 2 points; loud, filled the air, recorded as 3 minutes. A record of each lung function PEF%, FEV1% value.Result: 56 cases of children with no exit, the researchers carefully documented the clinical symptoms and signs, severity assessment score and pulmonary function values. Normal completion of visits, better compliance. Two groups of patients before treatment and the severity of the basic information was no significant difference. Experimental group medication 1 week, 2 weeks, 3 weeks after the illness and lung function improved significantly compared with the control group, experimental group 1 week after treatment, 2 weeks, 3 weeks compared with the baseline condition had significantly improved and pulmonary function improved and the medication 1 week for 3 weeks each visit, and lung function compared with the previous condition had significantly improved. The control group 1 week after drug cough, wheezing, difficulty breathing improvedcompared with before treatment was not significant, but the lungs wheezing sounds and lung function before treatment were significantly higher than improved, in After 2 weeks, 3 weeks after the illness and significant improvement in lung function than the previous. In this study most of the children's condition has been controlled, in the course of treatment without the occurrence of re-infection of. Medication during the trial group and control group children with no adverse reaction.Conclusion: Children use nebulized budesonide inhalation suspension pump and static points, dexamethasone treatment of children with asthma are valid. Application of nebulized budesonide inhalation suspension pump on asthma in children with cough, wheezing, breathing difficulties and lung wheezing sound mitigation and improvement in lung function are superior to static point of dexamethasone. Application of nebulized budesonide inhalation suspension pump treatment of childhood asthma hospitalization was significantly shorter than infusion of dexamethasone. Application of nebulized budesonide inhalation suspension pump treatment of children with acute asthma attack than the static point of dexamethasone can rapidly control the symptoms.